BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
Our results confirmed that BCMA CAR T-cell therapy combined with long-term pomalidomide had a low recurrence rate and manageable therapy-related side effects, providing a promising option for treating R/R MM.
Authors
- Erhua Wang
- Zuqun Deng
- Qian Cheng (ORCID: https://orcid.org/0000-0001-9791-6514)
- Yi‐Xuan Tu (ORCID: https://orcid.org/0000-0003-0769-6410)
- Liqing Kang (ORCID: https://orcid.org/0000-0002-9840-9060)
- Xin Li (ORCID: https://orcid.org/0000-0001-9024-7522)
- Liwen Wang (ORCID: https://orcid.org/0000-0003-1239-4927)
- Jing Liu (ORCID: https://orcid.org/0000-0002-7366-5287)
- Rui Liu (ORCID: https://orcid.org/0000-0003-2661-7183)
- Ling Chu
- Yan Yu (ORCID: https://orcid.org/0000-0001-5598-763X)
- Jian Zhang (ORCID: https://orcid.org/0000-0002-6055-0958)
- Yuhan Yan
Institutions
- Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1186/s12967-024-05772-w
- Citations
- 9
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.54
Funders
- National Natural Science Foundation of China